BRPI0513824A - derivados glucitol, seu pró-fármaco e seu sal e agente terapêutico contendo os mesmos para diabetes - Google Patents

derivados glucitol, seu pró-fármaco e seu sal e agente terapêutico contendo os mesmos para diabetes

Info

Publication number
BRPI0513824A
BRPI0513824A BRPI0513824-8A BRPI0513824A BRPI0513824A BR PI0513824 A BRPI0513824 A BR PI0513824A BR PI0513824 A BRPI0513824 A BR PI0513824A BR PI0513824 A BRPI0513824 A BR PI0513824A
Authority
BR
Brazil
Prior art keywords
diabetes
salt
prodrug
optionally substituted
therapeutic agent
Prior art date
Application number
BRPI0513824-8A
Other languages
English (en)
Inventor
Hiroharu Matsuoka
Tsutomu Sato
Masahiro Nishimoto
Yasuharu Kato
Masahiro Sakaitani
Sang-Hak Lee
Original Assignee
Chugai Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35786252&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0513824(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Chugai Pharmaceutical Co Ltd filed Critical Chugai Pharmaceutical Co Ltd
Publication of BRPI0513824A publication Critical patent/BRPI0513824A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Connection Of Plates (AREA)
  • Dowels (AREA)

Abstract

DERIVADOS GLUCITOL, SEU PRó-FáRMACO E SEU SAL E AGENTE TERAPêUTICO CONTENDO OS MESMOS PARA DIABETES. A presente invenção refere-se a um derivado de glucitol tendo a função de redução de um nível de açúcar no sangue e tendo de preferência propriedades exigidas de medicamentos, tais como atividade de fármaco de longa duração: e um composição médica para o uso na prevenção ou tratamento de doenças atribuíveis a hipergilcemia, tais como diabetes, complicações de diabetes, e obesidade. O derivado é um composto representado pela fórmula (I): em que m é um número inteiro selecionado entre 1-3; R¬ 1¬ a R¬ 4¬ cada um independentemente é alquila opcionalmente substituída, etc.; Ar¬ 1¬ é naftila opcionalmente substituída; e A é heteroarila opcionalmente substituída, um pró-fármaco do composto ou um seu sal farmaceuticamente aceitável de cada. Também providos são um medicamento, uma composição médica, e semelhantes cada um contendo o composto.
BRPI0513824-8A 2004-07-27 2005-07-27 derivados glucitol, seu pró-fármaco e seu sal e agente terapêutico contendo os mesmos para diabetes BRPI0513824A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2004218895 2004-07-27
JP2004343942 2004-11-29
PCT/JP2005/013716 WO2006011502A1 (ja) 2004-07-27 2005-07-27 新規なグルシトール誘導体、そのプロドラッグおよびその塩、ならびにそれらを含有する糖尿病治療薬

Publications (1)

Publication Number Publication Date
BRPI0513824A true BRPI0513824A (pt) 2008-05-20

Family

ID=35786252

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0513824-8A BRPI0513824A (pt) 2004-07-27 2005-07-27 derivados glucitol, seu pró-fármaco e seu sal e agente terapêutico contendo os mesmos para diabetes

Country Status (12)

Country Link
US (1) US7943748B2 (pt)
EP (1) EP1803721A4 (pt)
JP (1) JPWO2006011502A1 (pt)
KR (1) KR20070042191A (pt)
CN (2) CN1020944C (pt)
AU (1) AU2005265715A1 (pt)
BR (1) BRPI0513824A (pt)
CA (1) CA2574608A1 (pt)
MX (1) MX2007001101A (pt)
RU (1) RU2386631C2 (pt)
TW (1) TW200617001A (pt)
WO (1) WO2006011502A1 (pt)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE510834T1 (de) 2003-03-14 2011-06-15 Astellas Pharma Inc C-glykosid-derivate zur behandlung von diabetes
FR2883340B1 (fr) * 2005-03-16 2007-06-08 Itw De France Soc Par Actions Dispositif de fixation d'un anneau d'arrimage sur un element porteur et support le comportant
TW200726755A (en) * 2005-07-07 2007-07-16 Astellas Pharma Inc A crystalline choline salt of an azulene derivative
PE20080251A1 (es) 2006-05-04 2008-04-25 Boehringer Ingelheim Int Usos de inhibidores de dpp iv
WO2007140191A2 (en) 2006-05-23 2007-12-06 Theracos, Inc. Glucose transport inhibitors and methods of use
TWI403516B (zh) * 2006-07-27 2013-08-01 Chugai Pharmaceutical Co Ltd To replace spirocyclic alcohol derivatives, and its use as a therapeutic agent for diabetes
CA2664095A1 (en) * 2006-09-21 2008-03-27 Boehringer Ingelheim International Gmbh Glucopyranosyl-substituted difluorobenzyl-benzene derivatives, medicaments containing such compounds, their use and process for their manufacture
TWI499414B (zh) 2006-09-29 2015-09-11 Lexicon Pharmaceuticals Inc 鈉與葡萄糖第２型共同運輸體（ｃｏ-ｔｒａｎｓｐｏｒｔｅｒ ２）的抑制物與其應用方法
CA2673498C (en) * 2006-12-21 2012-04-24 Astellas Pharma Inc. Method for producing c-glycoside derivative and intermediate for synthesis thereof
US7795228B2 (en) 2006-12-28 2010-09-14 Theracos, Inc. Spiroheterocyclic glycosides and methods of use
US7846945B2 (en) 2007-03-08 2010-12-07 Lexicon Pharmaceuticals, Inc. Piperdine-based inhibitors of sodium glucose co-transporter 2 and methods of their use
UA101004C2 (en) 2007-12-13 2013-02-25 Теракос, Инк. Derivatives of benzylphenylcyclohexane and use thereof
CL2008003653A1 (es) 2008-01-17 2010-03-05 Mitsubishi Tanabe Pharma Corp Uso de un inhibidor de sglt derivado de glucopiranosilo y un inhibidor de dppiv seleccionado para tratar la diabetes; y composicion farmaceutica.
MX2011001855A (es) 2008-08-22 2011-03-24 Theracos Inc Procesos para la preparacion de inhibidores de sglt2.
ES2380408T3 (es) * 2008-08-28 2012-05-11 Pfizer Inc. Derivados de dioxa-biciclo[3.2.1]octano-2,3,4-triol
PT3228320T (pt) 2008-10-17 2020-03-26 Sanofi Aventis Deutschland Combinação de uma insulina e de um agonista do glp-1
CN101830876A (zh) * 2009-03-12 2010-09-15 上海恒瑞医药有限公司 C-芳基葡萄糖苷衍生物、其制备方法及其在医药上的应用
WO2010128152A1 (en) * 2009-05-07 2010-11-11 Novartis Ag Fused heterocyclic c-glycosides for the treatment of diabetes
KR20120087950A (ko) 2009-10-20 2012-08-07 노파르티스 아게 글리코시드 유도체 및 그의 용도
US8163704B2 (en) 2009-10-20 2012-04-24 Novartis Ag Glycoside derivatives and uses thereof
US8669380B2 (en) 2009-11-02 2014-03-11 Pfizer Inc. Dioxa-bicyclo[3.2.1]octane-2,3,4-triol derivatives
SG10201500871TA (en) 2009-11-13 2015-04-29 Sanofi Aventis Deutschland Pharmaceutical composition comprising a glp-1 agonist and methionine
JP5832439B2 (ja) 2009-11-13 2015-12-16 サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング Ｇｌｐ−１アゴニスト、インスリン及びメチオニンを含む薬学的組成物
WO2011153712A1 (en) 2010-06-12 2011-12-15 Theracos, Inc. Crystalline form of benzylbenzene sglt2 inhibitor
CN102372722A (zh) 2010-08-10 2012-03-14 江苏恒瑞医药股份有限公司 C-芳基葡萄糖苷衍生物、其制备方法及其在医药上的应用
CN103179978A (zh) * 2010-08-30 2013-06-26 赛诺菲-安万特德国有限公司 Ave0010用于制造供治疗2型糖尿病用的药物的用途
JP6105489B2 (ja) 2011-02-18 2017-03-29 シャンハイ インリ ファーマシューティカル カンパニー リミティド アリールグルコシド化合物、その調製方法及び使用
JP2014510782A (ja) 2011-04-14 2014-05-01 ノバルティス アーゲー グリコシド誘導体およびその使用
US8614195B2 (en) 2011-04-14 2013-12-24 Novartis Ag Glycoside derivatives and uses thereof
US9821032B2 (en) 2011-05-13 2017-11-21 Sanofi-Aventis Deutschland Gmbh Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin
JP6367115B2 (ja) 2011-08-29 2018-08-01 サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング ２型糖尿病患者の血糖コントロールに使用する組合せ医薬
TWI559929B (en) 2011-09-01 2016-12-01 Sanofi Aventis Deutschland Pharmaceutical composition for use in the treatment of a neurodegenerative disease
WO2013152476A1 (en) 2012-04-10 2013-10-17 Theracos, Inc. Process for the preparation of benzylbenzene sglt2 inhibitors
KR20140054800A (ko) * 2012-10-29 2014-05-09 주식회사 종근당바이오 1-데옥시-1-(2-하이드록시에틸 아미노)-d-글루시톨 및 미글리톨의 제조방법
CN103910769B (zh) 2012-12-31 2018-10-02 上海璎黎药业有限公司 葡萄糖衍生物和脯氨酸的复合物、晶体、制备方法及应用
CN104447893B (zh) * 2013-09-25 2018-01-23 广东东阳光药业有限公司 吡喃葡萄糖基衍生物及其在医药上的应用
WO2015051484A1 (en) 2013-10-12 2015-04-16 Theracos, Inc. Preparation of hydroxy-benzylbenzene derivatives
CN107206058A (zh) 2014-12-12 2017-09-26 赛诺菲-安万特德国有限公司 甘精胰岛素/利西拉来固定比率配制剂
TWI748945B (zh) 2015-03-13 2021-12-11 德商賽諾菲阿凡提斯德意志有限公司 第２型糖尿病病患治療
TW201705975A (zh) 2015-03-18 2017-02-16 賽諾菲阿凡提斯德意志有限公司 第２型糖尿病病患之治療
CN105156426A (zh) * 2015-10-28 2015-12-16 苏州道众机械制造有限公司 一种膨胀螺栓
KR101954188B1 (ko) * 2017-02-24 2019-05-23 동아에스티주식회사 Sglt-2 억제제인 신규 글루코스 유도체
US11454128B2 (en) * 2018-08-06 2022-09-27 General Electric Company Fairing assembly
WO2020151620A1 (zh) * 2019-01-24 2020-07-30 北京盈科瑞创新药物研究有限公司 化合物、其制备方法及其作为药物中间体的应用
CN115523208A (zh) * 2021-06-24 2022-12-27 宾科精密部件(中国)有限公司 一种嵌入式紧固组件和安装组件以及安装方法

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2102591C (en) 1992-11-12 2000-12-26 Kenji Tsujihara Hypoglycemic agent
US5837689A (en) * 1993-06-16 1998-11-17 Glycomed Incorporated Sialyl lewis-x mimetics containing naphthyl backbones
US5830873A (en) 1994-05-11 1998-11-03 Tanabe Seiyaku Co., Ltd. Propiophenone derivative and a process for preparing the same
JP2814950B2 (ja) 1994-05-11 1998-10-27 田辺製薬株式会社 血糖降下剤
US5614639A (en) * 1995-03-31 1997-03-25 Eli Lilly And Company Process for preparing 2-substituted benzo[b]thiophene compounds and intermediates thereof
WO1997001335A1 (en) * 1995-06-29 1997-01-16 Texas Biotechnology Corporation Di- and trivalent small molecule selectin inhibitors
JP3034192B2 (ja) 1995-11-07 2000-04-17 田辺製薬株式会社 プロピオフェノン誘導体およびその製法
JP3006513B2 (ja) 1995-11-07 2000-02-07 田辺製薬株式会社 医薬組成物
JP3065235B2 (ja) 1995-11-07 2000-07-17 田辺製薬株式会社 プロピオフェノン誘導体およびその製法
ATE216704T1 (de) * 1996-12-26 2002-05-15 Tanabe Seiyaku Co Propiophenonderivate und verfahren zu ihrer herstellung
JP2000080041A (ja) 1998-03-09 2000-03-21 Tanabe Seiyaku Co Ltd 医薬組成物
EP1213296B1 (en) 1999-08-31 2004-04-14 Kissei Pharmaceutical Co., Ltd. Glucopyranosyloxypyrazole derivatives, medicinal compositions containing the same and intermediates in the production thereof
PH12000002657B1 (en) * 1999-10-12 2006-02-21 Bristol Myers Squibb Co C-aryl glucoside SGLT2 inhibitors
US6515117B2 (en) * 1999-10-12 2003-02-04 Bristol-Myers Squibb Company C-aryl glucoside SGLT2 inhibitors and method
US6627611B2 (en) * 2000-02-02 2003-09-30 Kotobuki Pharmaceutical Co Ltd C-glycosides and preparation of thereof as antidiabetic agents
JP4456768B2 (ja) * 2000-02-02 2010-04-28 壽製薬株式会社 Ｃ−配糖体を含有する薬剤
ES2254376T3 (es) 2000-03-17 2006-06-16 Kissei Pharmaceutical Co., Ltd. Derivados glucopiranosiloxibencilbenceno, preparaciones medicinales que los contienen e intermediarios para la preparacion de los indicados derivados.
US6555519B2 (en) 2000-03-30 2003-04-29 Bristol-Myers Squibb Company O-glucosylated benzamide SGLT2 inhibitors and method
US6683056B2 (en) 2000-03-30 2004-01-27 Bristol-Myers Squibb Company O-aryl glucoside SGLT2 inhibitors and method
JP3798375B2 (ja) 2000-09-29 2006-07-19 キッセイ薬品工業株式会社 グルコピラノシルオキシベンジルベンゼン誘導体およびそれを含有する医薬組成物
WO2002036602A1 (en) 2000-11-02 2002-05-10 Ajinomoto Co., Inc. Novel pyrazole derivatives and diabetes remedies containing the same
WO2002044192A1 (en) 2000-11-30 2002-06-06 Kissei Pharmaceutical Co., Ltd. Glucopyranosyloxybenzyl benzene derivatives, medicinal compositions containing the same and intermediates in the production thereof
SK287786B6 (sk) 2000-12-28 2011-09-05 Kissei Pharmaceutical Co., Ltd. Glukopyranosyloxypyrazolový derivát, farmaceutická kompozícia alebo kombinácia s jeho obsahom a ich použitie
TWI255817B (en) 2001-02-14 2006-06-01 Kissei Pharmaceutical Glucopyranosyloxybenzylbenzene derivatives and medicinal use thereof
EP1364957B1 (en) 2001-02-26 2008-12-31 Kissei Pharmaceutical Co., Ltd. Glycopyranosyloxypyrazole derivatives and medicinal use thereof
WO2002068440A1 (en) 2001-02-27 2002-09-06 Kissei Pharmaceutical Co., Ltd. Glycopyranosyloxypyrazole derivatives and medicinal use thereof
US6936590B2 (en) * 2001-03-13 2005-08-30 Bristol Myers Squibb Company C-aryl glucoside SGLT2 inhibitors and method
DK1385856T3 (da) * 2001-04-11 2006-05-15 Bristol Myers Squibb Co Aminosyrekomplekser af C-aryl-glucosider til behandling af diabetes og fremgangsmåder
EP1389621A4 (en) 2001-04-27 2005-05-11 Ajinomoto Kk N-SUBSTITUTED PYRAZOLYL-O-GLYCOSIDE DERIVATIVES AND DIABETES CONTAINING THEREOF
CA2448741C (en) 2001-05-30 2010-06-22 Kissei Pharmaceutical Co., Ltd. Glucopyranosyloxypyrazole derivative, medicinal composition containing the same, medicinal use thereof, and intermediate therefor
US7271153B2 (en) 2001-06-20 2007-09-18 Kissei Pharmaceutical Co., Ltd. Nitrogenous heterocyclic derivatives, medicinal compositions containing the same, medicinal uses thereof, and intermediates therefor
JP4115105B2 (ja) 2001-07-02 2008-07-09 協和醗酵工業株式会社 ピラゾール誘導体
WO2003011880A1 (fr) 2001-07-31 2003-02-13 Kissei Pharmaceutical Co., Ltd. Derive de glucopyranosyloxybenzylbenzene, composition medicinale contenant ce derive, usage medicinal de cette composition et produit intermediaire pour produire cette composition
US20030087843A1 (en) 2001-09-05 2003-05-08 Washburn William N. O-pyrazole glucoside SGLT2 inhibitors and method of use
CA2484306A1 (en) 2002-04-26 2003-11-06 Katsumi Maezono Prophylactic and therapeutic agent of diabetes mellitus
DE10231370B4 (de) 2002-07-11 2006-04-06 Sanofi-Aventis Deutschland Gmbh Thiophenglycosidderivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zur Herstellung dieser Arzneimittel
TWI254635B (en) * 2002-08-05 2006-05-11 Yamanouchi Pharma Co Ltd Azulene derivative and salt thereof
MXPA05000725A (es) 2002-08-09 2005-04-08 Taisho Pharma Co Ltd Procedimiento para la produccion selectiva de aril-5-tio-??-d-aldohexopiranosidos.
DE10258007B4 (de) 2002-12-12 2006-02-09 Sanofi-Aventis Deutschland Gmbh Aromatische Fluorglycosidderivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zur Herstellung dieser Arzneimittel
DE10258008B4 (de) 2002-12-12 2006-02-02 Sanofi-Aventis Deutschland Gmbh Heterocyclische Fluorglycosidderivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zur Herstellung dieser Arzneimittel
AU2003289440A1 (en) 2002-12-25 2004-07-22 Kissei Pharmaceutical Co., Ltd. Nitrogen-containing heterocycic derivatives, medicinal compositions containing the same and medicinal use thereof
ATE510834T1 (de) * 2003-03-14 2011-06-15 Astellas Pharma Inc C-glykosid-derivate zur behandlung von diabetes
CN104109155A (zh) * 2003-08-01 2014-10-22 田边三菱制药株式会社 新颖化合物

Also Published As

Publication number Publication date
US20080319047A1 (en) 2008-12-25
AU2005265715A1 (en) 2006-02-02
RU2007107076A (ru) 2008-09-10
TW200617001A (en) 2006-06-01
CN1989132A (zh) 2007-06-27
RU2386631C2 (ru) 2010-04-20
CN1053827A (zh) 1991-08-14
WO2006011502A1 (ja) 2006-02-02
CN1020944C (zh) 1993-05-26
JPWO2006011502A1 (ja) 2008-05-01
US7943748B2 (en) 2011-05-17
EP1803721A1 (en) 2007-07-04
CA2574608A1 (en) 2006-02-02
EP1803721A4 (en) 2009-05-20
KR20070042191A (ko) 2007-04-20
MX2007001101A (es) 2007-03-15
CN1989132B (zh) 2010-06-09

Similar Documents

Publication Publication Date Title
BRPI0513752A (pt) derivado de ciclohexano, pró-droga do mesmo e sal do mesmo e agente terapêutico contendo o mesmo para diabetes
BRPI0313694B8 (pt) derivados de pirazol, composição medicinal contendo os mesmos, seu uso medicinal e intermediários para sua produção
BR0013667A (pt) Derivados de glucopiranosiloxipirazol, composições medicinais contendo os mesmos derivados e seus intermediários na produção dos mesmos
EP1803721A4 (en) NEW GLUCITOL DERIVATIVE, PRODRUG THEREOF AND SALT AND THERAPEUTIC AGENT AGAINST DIABETES CONTAINING THIS
NO20064201L (no) Glukopyranosylsubstituerte benzolderivater, medikamenter inneholdende slike forbindelser, deres anvendelse og fremstilling
BRPI0515482A (pt) derivados heterocìclicos e seus usos como agentes terapêuticos
NO20076425L (no) Fremgangsmater for behandling av drug-resistent cancer
BRPI0714908B8 (pt) derivados de pirimidina como inibidor de pi3k, composição farmacêutica e agente preventivo ou agente terapêutico de uma doença proliferativa que os compreende
NO20070576L (no) Nye hydantionderivater for behandling av obstruktive luftveissykdommer.
BRPI0515488A (pt) derivados de heterocìclicos e seu uso como agentes terapêuticos
NO20065904L (no) Terapeutiske forbindelser
NO20082445L (no) Neuropeptid-2 reseptor-agonister
TW200838549A (en) Methods for preventing and treating neurodegenerative disorders
NO950774L (no) Fremgangsmåte for inhibering av bentap og nedsettelse av serumkolesterol
BR0315580A (pt) Derivados de metileno uréia
TW200736223A (en) N-(pyridin-2-yl)-sulfonamide derivatives
BR0317524A (pt) Compostos derivados de pirrolopirimidina, composição farmacêutica, processo para as suas preparações e respectivo uso
NO20050569L (no) Fremgangsmate for behandling av alvorlig hjertesvikt og medikament for dette
BR0316364A (pt) Combinação de terapia do câncer com um composto anticâncer ativado com gst e uma outra terapia anticâncer
BRPI0518231A2 (pt) derivados de 2-amido-4-feniltiazol, o respectivo preparo e a respectiva aplicaÇço em terapÊutica
BR9807950A (pt) Composto, composição farmacêutica, uso de um composto, e, processos para tratar ou reduzir o risco de doenças ou condições humanas, o risco de doença inflamatória o risco da dor e para a preparação de um composto
BRPI0408744A (pt) 4-feniltetrahidroisoquinolinas substituìdas, processos para preparação das mesmas, seu uso como medicamento, bem como medicamento que contém as mesmas
UY29085A1 (es) Derivados de pirimidina 4-sulfonamido sustituidos, compuestos intermedios para su preparación, procedimientos de preparación, composiciones medicinales conteniéndolos y aplicaci0nes
CA2335366A1 (en) Compositions and methods for treating elevated blood cholesterol
DK1778680T3 (da) Spirocykliske cyclohexaderivater

Legal Events

Date Code Title Description
B08F Application fees: application dismissed [chapter 8.6 patent gazette]

Free format text: REFERENTE A 7A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: NAO APRESENTADA A GUIA DE CUMPRIMENTO DE EXIGENCIA. REFERENTE A 7A ANUIDADE.